The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Vivos Therapeutics (VVOS) announced a delay in filing its Form 10-Q for the quarter ended March 31, 2026, to allow additional time to consolidate financial data from its recent acquisition of The Sleep Center of Nevada (SCN). The company expects a larger net loss due to higher SG&A expenses related to the SCN integration, according to preliminary reports that also indicated revenue growth.
Sign in to access this content
Sign InThe delay comes amid volatility in small-cap stocks, with VVOS shares seeing limited recent trading activity. Companies that delay SEC filings often face regulatory scrutiny, particularly in complex merger cases. However, the preliminary revenue growth may partially offset the negative sentiment, per market data.
No closing price for VVOS was available in the pre-fetched data, but investors are closely monitoring any updates from the company. No major economic events in the next seven days are expected to directly impact the stock, leaving the focus on the company's ability to file within the 5-day grace period.